Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Distribution of response types among patients treated with cis-platinum

From: Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Response Number Evidence of progression Time to progression Median (months) Number deceased
Complete 9 9 17 6
Partial 7 7 8 6
Stable 3 3 3 3
Progressive 1 1 1 1